A large phase 3 clinical trial for cystic fibrosis patients has concluded, showing that a combination of two new cystic fibrosis drugs modestly improved lung function and offered better health outcomes for some patients. Now, scientists have shown that one of these drugs counteracts the intended beneficial molecular effect of the other.